Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT02982850
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 120 participants
- Registry
-
NCT02982850
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02982850. Randomized; no masking; primary purpose treatment. Start 2016-12 (registry gives no type); primary completion 2020-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease
- Acronym
- DECISIVE
- Condition
- Atrial Fibrillation
- Condition
- Valve Heart Disease
- Intervention (Drug)
- Dabigatran
- Intervention (Drug)
- Acetylsalicylic acid
- Intervention (Drug)
- Warfarin
- Lead sponsor
- Asan Medical Center
- Collaborator
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct02982850- Content hash
76c170d3906db206bf8f6171643bc800d6e394eda6afa29fd9afb74d88713aa9